FDA Approves Quark IND for DGFi, an siRNA therapeutic based on Silence Therapeutics’ Proprietary Chemistry
News Jun 26, 2008
Silence Therapeutics plc announces that the U.S. Food and Drug Administration (FDA) has approved a Quark Pharmaceuticals Inc (Quark) Investigational New Drug application (IND) for an siRNA therapeutic product based on Silence’s proprietary chemistry.
The product, DGFi, was discovered and is being developed by Quark for use in kidney transplantation. Rights to the AtuRNAi structure of DGFi were licensed to Quark by Silence Therapeutics.
DGFi is being investigated for the prevention and treatment of Delayed Graft Function (DGF) associated with renal transplantation. DGF is a syndrome caused by ischemia and reperfusion injury, which frequently occurs in kidneys once they are removed from a donor and transplanted into the patient.
In patients with DGF, the transplanted kidney does not function properly and requires intervention by dialysis. DGFi is designed to temporarily inhibit the activity of the p53 gene, which is associated with apoptosis, also known as programmed cell death, and is believed to be critical in the ischemia and reperfusion injury process.
DGFi uses the same active AtuRNAi molecule as AKIi-5, which Quark is developing for treatment of Acute Kidney Injury.
Jeff Vick, Chief Executive Officer of Silence Therapeutics, said “We are very excited by this news, as it is the third IND approved for a product based upon our proprietary AtuRNAi chemistry and confirms our leading position in this revolutionary field of technology.”
Largest Genetic Study of Osteoarthritis Advances ResearchNews
Osteoarthritis is a complex disease, and the genetic basis of the disease has proved difficult to pin down. A new study from the Sanger Institute provides much-needed hope.READ MORE
The DNA Shuffle: Barcoding Trick is Boost to RNA-SeqNews
SPLiT-seq is a new technology that can separate thousands of cells using innovative barcoding technology.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018